

Andrea Ries Thurman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2311302/publications.pdf>

Version: 2024-02-01

45
papers

911
citations

516710

16
h-index

477307

29
g-index

47
all docs

47
docs citations

47
times ranked

1064
citing authors

#	ARTICLE	IF	CITATIONS
1	One-Year Follow-up of Women With Unfulfilled Postpartum Sterilization Requests. <i>Obstetrics and Gynecology</i> , 2010, 116, 1071-1077.	2.4	103
2	Innate Immunity and Inflammatory Response to <i>Trichomonas vaginalis</i> and Bacterial Vaginosis: Relationship to HIV Acquisition. <i>American Journal of Reproductive Immunology</i> , 2011, 65, 89-98.	1.2	93
3	Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1139-1152.	1.1	93
4	Depot Medroxyprogesterone Acetate Increases Immune Cell Numbers and Activation Markers in Human Vaginal Mucosal Tissues. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 592-601.	1.1	92
5	Multipurpose Prevention Technologies: Biomedical Tools to Prevent HIV-1, HSV-2, and Unintended Pregnancies. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2011, 2011, 1-10.	1.5	60
6	Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. <i>PLoS ONE</i> , 2018, 13, e0199778.	2.5	53
7	Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity. <i>Journal of Clinical Investigation</i> , 2018, 128, 4622-4638.	8.2	33
8	Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 807-819.	1.1	28
9	Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. <i>EClinicalMedicine</i> , 2021, 36, 100893.	7.1	27
10	Effects of Hormonal Contraception on Antiretroviral Drug Metabolism, Pharmacokinetics and Pharmacodynamics. <i>American Journal of Reproductive Immunology</i> , 2014, 71, 523-530.	1.2	25
11	Comparison of Follicular and Luteal Phase Mucosal Markers of HIV Susceptibility in Healthy Women. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 547-560.	1.1	24
12	Quantitative modeling predicts mechanistic links between pre-treatment microbiome composition and metronidazole efficacy in bacterial vaginosis. <i>Nature Communications</i> , 2020, 11, 6147.	12.8	24
13	Topical Inserts: A Versatile Delivery Form for HIV Prevention. <i>Pharmaceutics</i> , 2019, 11, 374.	4.5	22
14	Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings. <i>PLoS ONE</i> , 2019, 14, e0217229.	2.5	21
15	Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 225.e1-225.e15.	1.3	20
16	Unfulfilled postpartum sterilization requests. <i>Journal of reproductive medicine, The</i> , 2009, 54, 467-72.	0.2	20
17	Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics. <i>Contraception</i> , 2013, 87, 738-743.	1.5	18
18	Assessment of the vaginal residence time of biomarkers of semen exposure. <i>Contraception</i> , 2016, 94, 512-520.	1.5	15

#	ARTICLE	IF	CITATIONS
19	A phase I randomized postcoital testing and safety study of the Caya diaphragm used with 3% Nonoxynol-9 gel, ContraGel or no gel. <i>Contraception</i> , 2017, 96, 124-130.	1.5	15
20	Analytical Advances in the <i>Ex Vivo</i> Challenge Efficacy Assay. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 395-403.	1.1	14
21	Post-cesarean delivery infectious morbidity: Focus on preoperative antibiotics and methicillin-resistant <i>Staphylococcus aureus</i> . <i>American Journal of Infection Control</i> , 2010, 38, 612-616.	2.3	12
22	The Effect of Hormonal Contraception on Cervicovaginal Mucosal End Points Associated with HIV Acquisition. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 853-864.	1.1	11
23	Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 79-88.	2.1	11
24	An alternative monitoring protocol for single-dose methotrexate therapy in ectopic pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 139.e1-139.e6.	1.3	8
25	Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 799501.	3.9	8
26	Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 82-92.	2.1	7
27	HIV Pre-exposure Prophylaxis Implant Stated Preferences and Priorities: Results of a Discrete Choice Experiment Among Women and Adolescent Girls in Gauteng Province, South Africa. <i>AIDS and Behavior</i> , 2022, 26, 3099-3109.	2.7	7
28	Comparison of Visual and Ultraviolet Light Inspection Versus DNA/Protein Biomarkers to Assess Product Adherence With Vaginal Microbicide Applicators. <i>Sexually Transmitted Diseases</i> , 2014, 41, 739-746.	1.7	6
29	Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies. <i>Clinical and Translational Medicine</i> , 2018, 7, 37.	4.0	6
30	Genital mucosal drug concentrations and anti-HIV activity in tenofovir-based PrEP products. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 87-97.	2.1	6
31	Currently available combined oral contraception. <i>Expert Review of Obstetrics and Gynecology</i> , 2011, 6, 525-538.	0.4	5
32	Acceptability of a Long-Acting, Multipurpose Vaginal Ring: Findings from a Phase I Trial in the U.S. and Dominican Republic. <i>Journal of Women's Health</i> , 2022, 31, 1343-1352.	3.3	5
33	Multicompartmental Pharmacokinetics of Tenofovir 1% Gel Using the BAT 24 Regimen Versus Daily and Single Pericoital Dosing. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A37-A37.	1.1	4
34	Rapid measures of userâ€™s adherence to vaginal drug products using attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) and multivariate discriminant techniques. <i>PLoS ONE</i> , 2018, 13, e0197906.	2.5	4
35	Development of a Composite Measure of Product Adherence, Protocol Compliance, and Semen Exposure Using DNA and Protein Biomarkers for Topical HIV Prevention Studies. <i>PLoS ONE</i> , 2014, 9, e114368.	2.5	4
36	The Male Sexual Partners of Adult Versus Teen Women With Sexually Transmitted Infections. <i>Sexually Transmitted Diseases</i> , 2009, 36, 768-774.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Vitamin D Status Impacts Genital Mucosal Immunity and Markers of HIV-1 Susceptibility in Women. <i>Nutrients</i> , 2020, 12, 3176.	4.1	2
38	A phase I randomized safety study of a single-size silicone rubber diaphragm used with or without a lactic-acid-containing diaphragm gel. <i>Contraception</i> , 2019, 100, 430-437.	1.5	1
39	Application of a composite measure of product adherence, protocol compliance, and semen exposure to a phase III microbicide HIV prevention trial. <i>Translational Medicine Communications</i> , 2021, 6, .	1.4	1
40	Mucosal Susceptibility to HIV-1 and Tenofovir Protection in Explanted Cervicovaginal Tissues from Postmenopausal Compared to Premenopausal Women. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A264-A265.	1.1	0
41	Gene Expression Analysis of Human Vaginal Mucosal Response to Pro-inflammatory Stimuli - Identification of Biomarkers of Vaginal Inflammation. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A239-A239.	1.1	0
42	Effect of Bacterial Vaginosis on Markers of Genital Tract Inflammation and Mucosal Immunity: Mechanisms for Susceptibility to HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A30-A30.	1.1	0
43	Assessment of the Vaginal Residence Time of Biomarkers of Semen Exposure. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A172-A172.	1.1	0
44	The use of objective adherence measures targeting four placebo microbicide delivery forms in the Quatro Clinical Crossover Study. <i>Clinical and Translational Discovery</i> , 2021, 1, e13.	0.5	0
45	Cryopreservation Does Not Affect the Clinical Pregnancy Rate of Blastocysts Derived from Vitrified Oocytes. <i>Scientific Reports</i> , 2022, 12, .	3.3	0